Laband Syndrome Therapeutics Market

Laband syndrome therapeutics sales will expand through 2036, with NSAIDs holding 47.3% of the drug class segment in 2026. Oral administration leads the route of administration segment with a 52.1% share. The market is projected to reach USD 3.5 billion in 2026 and USD 5.53 billion by 2036.